Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions

@@ label / en / label / en @@
+Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients
@@ label / fr / label / fr @@
+Développement d’inhibiteurs de l’AHR pour le traitement antiviral oral chez les patients atteints de COVID-19
@@ label / de / label / de @@
+Entwicklung von AhR-Inhibitoren zur oralen antiviralen Therapie für COVID-19-Patienten
@@ label / it / label / it @@
+Sviluppo di inibitori di AhR per la terapia antivirale orale per i pazienti affetti da COVID-19
@@ label / es / label / es @@
+Desarrollo de inhibidores de la AhR para la terapia antiviral oral para pacientes con COVID-19
@@ label / el / label / el @@
+Ανάπτυξη αναστολέων AhR για από του στόματος αντιιική θεραπεία για ασθενείς με COVID-19
@@ label / da / label / da @@
+Udvikling af AhR-hæmmere til oral antiviral behandling til covid-19-patienter
@@ label / fi / label / fi @@
+AhR-estäjien kehittäminen suun kautta otettavaa viruslääkitystä varten covid-19-potilaille
@@ label / mt / label / mt @@
+L-iżvilupp ta’ inibituri AhR għal terapija antivirali orali għall-pazjenti bil-COVID-19
@@ label / lv / label / lv @@
+AhR inhibitoru izstrāde perorālai pretvīrusu terapijai Covid-19 pacientiem
@@ label / sk / label / sk @@
+Vývoj inhibítorov AhR na perorálnu antivírusovú terapiu u pacientov s ochorením COVID-19
@@ label / ga / label / ga @@
+Coscairí AhR a fhorbairt le haghaidh teiripe frithvíreasach béil d’othair COVID-19
@@ label / cs / label / cs @@
+Vývoj inhibitorů AhR pro perorální antivirovou léčbu u pacientů s onemocněním COVID-19
@@ label / pt / label / pt @@
+Desenvolvimento de inibidores da AhR para terapêutica antiviral oral em doentes com COVID-19
@@ label / et / label / et @@
+AhR inhibiitorite väljatöötamine suukaudseks viirusevastaseks raviks COVID-19 patsientidel
@@ label / hu / label / hu @@
+Orális antivirális kezelésre szolgáló AhR-inhibitorok kifejlesztése Covid19-betegek esetében
@@ label / bg / label / bg @@
+Разработване на инхибитори на AhR за перорална антивирусна терапия при пациенти с COVID-19
@@ label / lt / label / lt @@
+AhR inhibitorių kūrimas geriamajam antivirusiniam gydymui COVID-19 pacientams
@@ label / hr / label / hr @@
+Razvoj AhR inhibitora za oralnu antivirusnu terapiju za bolesnike s bolešću COVID-19
@@ label / sv / label / sv @@
+Utveckling av AhR-hämmare för oral antiviral behandling för covid-19-patienter
@@ label / ro / label / ro @@
+Dezvoltarea inhibitorilor AhR pentru terapia antivirală orală pentru pacienții cu COVID-19
@@ label / sl / label / sl @@
+Razvoj zaviralcev AhR za peroralno protivirusno zdravljenje bolnikov s COVID-19
@@ label / pl / label / pl @@
+Opracowanie inhibitorów AhR do doustnej terapii przeciwwirusowej u pacjentów z COVID-19
@@ description / bg / description / bg @@
+Проект Q3988868 в Холандия
@@ description / hr / description / hr @@
+Projekt Q3988868 u Nizozemskoj
@@ description / hu / description / hu @@
+Projekt Q3988868 Hollandiában
@@ description / cs / description / cs @@
+Projekt Q3988868 v Nizozemsku
@@ description / da / description / da @@
+Projekt Q3988868 i Holland
@@ description / nl / description / nl @@
+Project Q3988868 in Nederland
@@ description / et / description / et @@
+Projekt Q3988868 Hollandis
@@ description / fi / description / fi @@
+Projekti Q3988868 Alankomaissa
@@ description / fr / description / fr @@
+Projet Q3988868 aux Pays-Bas
@@ description / de / description / de @@
+Projekt Q3988868 in den Niederlanden
@@ description / el / description / el @@
+Έργο Q3988868 στην Ολλανδία
@@ description / ga / description / ga @@
+Tionscadal Q3988868 san Ísiltír
@@ description / it / description / it @@
+Progetto Q3988868 nei Paesi Bassi
@@ description / lv / description / lv @@
+Projekts Q3988868 Nīderlandē
@@ description / lt / description / lt @@
+Projektas Q3988868 Nyderlanduose
@@ description / mt / description / mt @@
+Proġett Q3988868 fl-Olanda
@@ description / pl / description / pl @@
+Projekt Q3988868 w Holandii
@@ description / pt / description / pt @@
+Projeto Q3988868 na Holanda
@@ description / ro / description / ro @@
+Proiectul Q3988868 în Țările de Jos
@@ description / sk / description / sk @@
+Projekt Q3988868 v Holandsku
@@ description / sl / description / sl @@
+Projekt Q3988868 na Nizozemskem
@@ description / es / description / es @@
+Proyecto Q3988868 en Holanda
@@ description / sv / description / sv @@
+Projekt Q3988868 i Nederländerna
@@ Property / instance of @@
-Kohesio project
@@ Property / instance of: Kohesio project / rank @@
-Normal rank
@@ Property / financed by @@
-European Union
@@ Property / financed by: European Union / rank @@
-Normal rank
@@ Property / country @@
-Kingdom of the Netherlands
@@ Property / country: Kingdom of the Netherlands / rank @@
-Normal rank
@@ Property / start time @@
-June 2020Timestamp +2020-06-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2020-06-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / start time: 1 June 2020 / rank @@
-Normal rank
@@ Property / end time @@
-June 2021Timestamp +2021-06-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2021-06-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / end time: 1 June 2021 / rank @@
-Normal rank
@@ Property / beneficiary name (string) @@
-Hercules Pharmaceuticals
@@ Property / beneficiary name (string): Hercules Pharmaceuticals / rank @@
-Normal rank
@@ Property / beneficiary @@
-Q3985407
@@ Property / beneficiary: Q3985407 / rank @@
-Normal rank
@@ Property / EU contribution @@
-,362.0 EuroAmount 399,362.0 Euro
Unit Euro
-Amount
+,362.0 Euro
-Unit
+Euro
@@ Property / EU contribution: 399,362.0 Euro / rank @@
-Normal rank
@@ Property / budget @@
-,055,117.569 EuroAmount 1,055,117.569 Euro
Unit Euro
-Amount
+,055,117.569 Euro
-Unit
+Euro
@@ Property / budget: 1,055,117.569 Euro / rank @@
-Normal rank
@@ Property / co-financing rate @@
-.85 percentAmount 37.85 percent
Unit percent
-Amount
+.85 percent
-Unit
+percent
@@ Property / co-financing rate: 37.85 percent / rank @@
-Normal rank
@@ Property / fund @@
-European Regional Development Fund
@@ Property / fund: European Regional Development Fund / rank @@
-Normal rank
@@ Property / location (string) @@
-BD
@@ Property / location (string): 2333BD / rank @@
-Normal rank
@@ Property / programme @@
-North Netherlands - ERDF
@@ Property / programme: North Netherlands - ERDF / rank @@
-Normal rank
@@ Property / intervention field @@
-Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
-Normal rank
@@ Property / contained in Local Administrative Unit @@
+Groningen
@@ Property / contained in Local Administrative Unit: Groningen / rank @@
+Normal rank
@@ Property / instance of @@
+Kohesio project
@@ Property / instance of: Kohesio project / rank @@
+Normal rank
@@ Property / financed by @@
+European Union
@@ Property / financed by: European Union / rank @@
+Normal rank
@@ Property / start time @@
+June 2020Timestamp +2020-06-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2020-06-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / start time: 1 June 2020 / rank @@
+Normal rank
@@ Property / end time @@
+June 2021Timestamp +2021-06-01T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2021-06-01T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / end time: 1 June 2021 / rank @@
+Normal rank
@@ Property / fund @@
+European Regional Development Fund
@@ Property / fund: European Regional Development Fund / rank @@
+Normal rank
@@ Property / postal code @@
+BD
@@ Property / postal code: 2333BD / rank @@
+Normal rank
@@ Property / postal code @@
+AT
@@ Property / postal code: 9747AT / rank @@
+Normal rank
@@ Property / programme @@
+North Netherlands - ERDF
@@ Property / programme: North Netherlands - ERDF / rank @@
+Normal rank
@@ Property / intervention field @@
+Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)
+Normal rank
@@ Property / coordinate location @@
+°14'32.42"N, 6°31'47.86"ELatitude 53.24234001
Longitude 6.52995744
Precision 1.0E-5
Globe http://www.wikidata.org/entity/Q2
-Latitude
+.24234001
-Longitude
+.52995744
-Precision
+.0E-5
-Globe
+http://www.wikidata.org/entity/Q2
@@ Property / coordinate location: 53°14'32.42"N, 6°31'47.86"E / rank @@
+Normal rank
@@ Property / coordinate location @@
+°10'7.79"N, 4°28'2.14"ELatitude 52.168829066667
Longitude 4.4672636333333
Precision 1.0E-5
Globe http://www.wikidata.org/entity/Q2
-Latitude
+.168829066667
-Longitude
+.4672636333333
-Precision
+.0E-5
-Globe
+http://www.wikidata.org/entity/Q2
@@ Property / coordinate location: 52°10'7.79"N, 4°28'2.14"E / rank @@
+Normal rank
@@ Property / contained in NUTS @@
+Agglomeratie Leiden en Bollenstreek
@@ Property / contained in NUTS: Agglomeratie Leiden en Bollenstreek / rank @@
+Normal rank
@@ Property / contained in NUTS @@
+Overig Groningen
@@ Property / contained in NUTS: Overig Groningen / rank @@
+Normal rank
@@ Property / country @@
+Netherlands
@@ Property / country: Netherlands / rank @@
+Normal rank
@@ Property / summary @@
+Het COVID-19 virus resulteert wereldwijd in een grote maatschappelijke en economische schade. Tal van mensen overlijden aan het Corona virus en de druk op de gezondheidszorg is immens hoog. Om de pandemie te bestrijden hebben veel landen een (gedeeltelijke) lockdown ingesteld. Dit resulteert in een geringere besmettingsgraad maar heeft ook significante negatieve effecten op de economie. Er is dan ook een grote behoefte aan een vaccin of medicijn, bij voorkeur oraal, voor het COVID-19 virus.   Hercules Pharmaceuticals werkt aan inhibitoren voor de Aryl Hydrocarbon Receptor (AhR). De AhR receptor is geïdentificeerd als een belangrijk aanknopingspunt voor virale replicaties. Virussen gebruiken de AhR receptor om het immuunsysteem te omzeilen en endogene mechanismes, die virale replicaties verhinderen, te blokkeren. Samen met het bedrijf MercachemSyncom gaat Hercules Pharmaceuticals haar lead compound HP163 voor COVID-19 verder optimaliseren richting de kliniek. (Dutch)
+Normal rank
@@ Property / summary @@
+The COVID-19 virus results in a major societal and economic damage worldwide. Many people die of the Corona virus and the pressure on healthcare is immensely high. To combat the pandemic, many countries have put in place a (partial) lockdown. This results in a lower contagion rate but also has significant negative effects on the economy. There is therefore a great need for a vaccine or medicine, preferably orally, for the COVID-19 virus.   Hercules Pharmaceuticals works on inhibitors for the Aryl Hydrocarbon Receptor (AhR). The AhR receptor has been identified as an important connecting factor for viral replications. Viruses use the AhR receptor to bypass the immune system and block endogenous mechanisms, preventing viral replications. Together with MercachemSyncom, Hercules Pharmaceuticals will further optimise its lead compound HP163 for COVID-19 towards the clinic. (English)
+Normal rank
+point in time: 15 December 2021Timestamp +2021-12-15T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2021-12-15T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
+readability score: 0.9570971871491476Amount 0.9570971871491476
Unit 1
-Amount
+.9570971871491476
 Unit
@@ Property / summary @@
+Le virus de la COVID-19 entraîne des dommages sociétaux et économiques majeurs dans le monde entier. De nombreuses personnes meurent du virus Corona et la pression sur les soins de santé est extrêmement élevée. Pour lutter contre la pandémie, de nombreux pays ont mis en place un confinement (partiel). Il en résulte une baisse du taux de contagion, mais aussi des effets négatifs importants sur l’économie. Il existe donc un grand besoin d’un vaccin ou d’un médicament, de préférence oralement, pour le virus de la COVID-19.   Hercules Pharmaceuticals travaille sur les inhibiteurs du récepteur d’hydrocarbures d’Aryl (AhR). Le récepteur AhR a été identifié comme un facteur de connexion important pour les répliques virales. Les virus utilisent le récepteur AhR pour contourner le système immunitaire et bloquer les mécanismes endogènes, empêchant les répliques virales. En collaboration avec MercachemSyncom, Hercules Pharmaceuticals optimisera davantage son composé principal HP163 pour la COVID-19 vers la clinique. (French)
+Normal rank
+point in time: 15 December 2021Timestamp +2021-12-15T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2021-12-15T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Das COVID-19-Virus führt weltweit zu einem großen gesellschaftlichen und wirtschaftlichen Schaden. Viele Menschen sterben an dem Corona-Virus und der Druck auf die Gesundheitsversorgung ist immens hoch. Um die Pandemie zu bekämpfen, haben viele Länder einen (teilweise) Lockdown eingerichtet. Dies führt zu einer niedrigeren Ansteckungsrate, hat aber auch erhebliche negative Auswirkungen auf die Wirtschaft. Es besteht daher ein großer Bedarf an Impfstoffen oder Medikamenten, vorzugsweise oral für das COVID-19-Virus.   Hercules Pharmaceuticals arbeitet an Hemmstoffen für den Arylhydrocarbon Receptor (AhR). Der AhR-Rezeptor wurde als wichtiger Bindefaktor für virale Replikationen identifiziert. Viren verwenden den AhR-Rezeptor, um das Immunsystem zu umgehen und endogene Mechanismen zu blockieren und virale Replikationen zu verhindern. Zusammen mit MercachemSyncom wird Hercules Pharmaceuticals seine Bleiverbindung HP163 für COVID-19 in Richtung Klinik weiter optimieren. (German)
+Normal rank
+point in time: 15 December 2021Timestamp +2021-12-15T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2021-12-15T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Il virus COVID-19 si traduce in un grave danno sociale ed economico a livello mondiale. Molte persone muoiono per il virus del Corona e la pressione sull'assistenza sanitaria è enormemente elevata. Per combattere la pandemia, molti paesi hanno posto in essere un confinamento (parziale). Ciò si traduce in un tasso di contagio inferiore, ma ha anche effetti negativi significativi sull'economia. Vi è quindi una grande necessità di un vaccino o di un medicinale, preferibilmente oralmente, per il virus della COVID-19.   Hercules Pharmaceuticals lavora sugli inibitori per il recettore di idrocarburi di arile (AhR). Il recettore AhR è stato identificato come un importante fattore di collegamento per le repliche virali. I virus usano il recettore AhR per bypassare il sistema immunitario e bloccare i meccanismi endogeni, prevenendo le repliche virali. Insieme a MercachemSyncom, Hercules Pharmaceuticals ottimizzerà ulteriormente il suo composto di piombo HP163 per la COVID-19 verso la clinica. (Italian)
+Normal rank
+point in time: 11 January 2022Timestamp +2022-01-11T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-01-11T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+El virus de la COVID-19 da lugar a un importante daño social y económico en todo el mundo. Muchas personas mueren por el virus Corona y la presión sobre la atención sanitaria es inmensamente alta. Para combatir la pandemia, muchos países han establecido un confinamiento (parcial). Esto da lugar a una menor tasa de contagio, pero también tiene efectos negativos significativos en la economía. Por lo tanto, existe una gran necesidad de vacuna o medicamento, preferiblemente oralmente, para el virus de la COVID-19.   Hercules Pharmaceuticals trabaja en inhibidores para el Receptor de Hidrocarburos Aryl (AhR). El receptor AhR ha sido identificado como un importante factor de conexión para replicaciones virales. Los virus utilizan el receptor AhR para eludir el sistema inmunitario y bloquear los mecanismos endógenos, evitando replicaciones virales. Junto con MercachemSyncom, Hercules Pharmaceuticals optimizará aún más su compuesto de plomo HP163 para COVID-19 hacia la clínica. (Spanish)
+Normal rank
+point in time: 12 January 2022Timestamp +2022-01-12T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-01-12T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Ο ιός COVID-19 έχει ως αποτέλεσμα σημαντική κοινωνική και οικονομική ζημία παγκοσμίως. Πολλοί άνθρωποι πεθαίνουν από τον ιό του κορονοϊού και η πίεση στην υγειονομική περίθαλψη είναι εξαιρετικά υψηλή. Για την καταπολέμηση της πανδημίας, πολλές χώρες έχουν θέσει σε εφαρμογή (μερικά) περιοριστικά μέτρα. Αυτό έχει ως αποτέλεσμα χαμηλότερο ποσοστό μετάδοσης, αλλά έχει επίσης σημαντικές αρνητικές επιπτώσεις στην οικονομία. Ως εκ τούτου, υπάρχει μεγάλη ανάγκη για εμβόλιο ή φάρμακο, κατά προτίμηση από το στόμα, για τον ιό COVID-19. Η Hercules Pharmaceuticals δρα στους αναστολείς του Aryl Hydrocarbon Receptor (AhR). Ο υποδοχέας AhR έχει αναγνωριστεί ως σημαντικός συνδετικός παράγοντας για τις ιικές αντιγραφές. Οι ιοί χρησιμοποιούν τον υποδοχέα AhR για να παρακάμψουν το ανοσοποιητικό σύστημα και να εμποδίσουν τους ενδογενείς μηχανισμούς, αποτρέποντας τις ιικές αντιπαραγωγές. Μαζί με την MercachemSyncom, η Hercules Pharmaceuticals θα βελτιστοποιήσει περαιτέρω την ένωση μολύβδου HP163 για τη νόσο COVID-19 προς την κλινική. (Greek)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Covid-19-virussen medfører store samfundsmæssige og økonomiske skader på verdensplan. Mange mennesker dør af coronavirusset, og presset på sundhedsvæsenet er enormt højt. For at bekæmpe pandemien har mange lande indført en (delvis) nedlukning. Dette resulterer i en lavere smitterate, men har også betydelige negative virkninger for økonomien. Der er derfor et stort behov for en vaccine eller et lægemiddel, helst mundtligt, mod covid-19-virusset. Hercules Pharmaceuticals arbejder på inhibitorer til Arylcarbon Receptor (AhR). AhR-receptoren er blevet identificeret som en vigtig forbindelsesfaktor for virale replikationer. Vira bruger AhR-receptoren til at omgå immunsystemet og blokere endogene mekanismer, hvilket forhindrer virale replikationer. Sammen med MercachemSyncom vil Hercules Pharmaceuticals yderligere optimere sin blyforbindelse HP163 for covid-19 mod klinikken. (Danish)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Covid-19-virus aiheuttaa merkittävää yhteiskunnallista ja taloudellista vahinkoa maailmanlaajuisesti. Monet ihmiset kuolevat koronavirukseen, ja terveydenhuoltoon kohdistuva paine on valtavan korkea. Pandemian torjumiseksi monet maat ovat ottaneet käyttöön (osittaiset) sulkutoimet. Tämä johtaa vähäisempään leviämisasteeseen, mutta sillä on myös merkittäviä kielteisiä vaikutuksia talouteen. Siksi covid-19-virusta varten tarvitaan kipeästi rokotetta tai lääkettä, mieluiten suullisesti. Hercules Pharmaceuticals vaikuttaa Aryl Hydrocarbon Receptorin (AhR) estäjiin. AhR-reseptori on tunnistettu tärkeäksi yhdistäväksi tekijäksi virusreplikaatioille. Virukset käyttävät AhR-reseptoria immuunijärjestelmän ohittamiseen ja endogeenisten mekanismien estämiseen, mikä estää virusten replikaatiot. Yhdessä MercachemSyncomin kanssa Hercules Pharmaceuticals optimoi edelleen lyijyyhdisteensä HP163 covid-19-tautia varten klinikalle. (Finnish)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Il-virus tal-COVID-19 jirriżulta f’dannu soċjetali u ekonomiku kbir madwar id-dinja. Ħafna nies imutu bil-virus tal-Corona u l-pressjoni fuq il-kura tas-saħħa hija għolja immens. Biex jiġġieldu l-pandemija, ħafna pajjiżi daħħlu fis-seħħ lockdown (parzjali). Dan jirriżulta f’rata ta’ kontaġju aktar baxxa iżda għandu wkoll effetti negattivi sinifikanti fuq l-ekonomija. Għalhekk hemm bżonn kbir ta’ vaċċin jew mediċina, preferibbilment bil-fomm, għall-virus tal-COVID-19. Hercules Farmaċewtiċi jaħdem fuq inibituri għar- Riċettur tal- Idrokarbonju Aryl (AhR). Ir-riċettur AhR ġie identifikat bħala fattur importanti ta’ konnessjoni għar-replikazzjonijiet virali. Il-virusijiet jużaw ir-riċettur AhR biex jevitaw is-sistema immunitarja u jimblukkaw il-mekkaniżmi endoġeni, u b’hekk jipprevjenu r-replikazzjonijiet virali. Flimkien ma’ MercachemSyncom, Hercules Pharmaceuticals se jkomplu jottimizzaw il-kompost ewlieni HP163 tiegħu għall-COVID-19 lejn il-klinika. (Maltese)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Covid-19 vīruss visā pasaulē rada lielus sociālus un ekonomiskus zaudējumus. Daudzi cilvēki mirst no koronavīrusa, un spiediens uz veselības aprūpi ir ārkārtīgi augsts. Lai apkarotu pandēmiju, daudzas valstis ir ieviesušas (daļēju) pārvietošanās ierobežojumu. Tas samazina kaitīgās ietekmes izplatīšanās rādītāju, bet tam ir arī būtiska negatīva ietekme uz ekonomiku. Tāpēc ir ļoti vajadzīga vakcīna vai zāles, vēlams iekšķīgi, pret Covid-19 vīrusu. Hercules Pharmaceuticals iedarbojas uz Aryl Ogļūdeņraža receptora (AhR) inhibitoriem. Ir konstatēts, ka AhR receptors ir svarīgs vīrusu replikāciju piesaistes faktors. Vīrusi izmanto AhR receptorus, lai apietu imūnsistēmu un bloķētu endogēnos mehānismus, novēršot vīrusu replikāciju. Kopā ar MercachemSyncom Hercules Pharmaceuticals turpinās optimizēt savu vadošo savienojumu HP163 Covid-19 ārstēšanai klīnikā. (Latvian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Vírus COVID-19 má za následok veľké spoločenské a hospodárske škody na celom svete. Mnohí ľudia zomrú na koronavírus a tlak na zdravotnú starostlivosť je nesmierne vysoký. V záujme boja proti pandémii mnohé krajiny zaviedli (čiastočnú) zákaz vychádzania. To má za následok nižšiu mieru nákazy, ale má aj významné negatívne účinky na hospodárstvo. Preto je pre vírus COVID-19 veľmi potrebná vakcína alebo liek, pokiaľ možno ústne. Hercules Pharmaceuticals účinkuje na inhibítory Arylkarbónového receptora (AhR). AhR receptor bol identifikovaný ako dôležitý spojovací faktor pre vírusové replikácie. Vírusy používajú AhR receptor na obídenie imunitného systému a blokujú endogénne mechanizmy, čím zabraňujú replikácii vírusu. Spolu s MercachemSyncom budú Hercules Pharmaceuticals ďalej optimalizovať svoju olovenú zlúčeninu HP163 pre COVID-19 smerom k klinike. (Slovak)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Déanann víreas COVID-19 dochar mór don tsochaí agus don gheilleagar ar fud an domhain. Faigheann go leor daoine bás de víreas an Choróinvíris agus tá an brú ar chúram sláinte thar a bheith ard. Chun an phaindéim a chomhrac, tá dianghlasáil (páirteach) curtha i bhfeidhm ag go leor tíortha. Bíonn ráta gabhála níos ísle mar thoradh air sin ach bíonn éifeachtaí diúltacha suntasacha aige ar an ngeilleagar freisin. Dá bhrí sin, tá géarghá le vacsaín nó leigheas, ó bhéal más féidir, le haghaidh víreas COVID-19. Oibríonn Cógaisíocht Hercules ar choscairí do Ghabhdóir Hidreacarbóin Aryl (AhR). Aithníodh an gabhdóir AhR mar fhachtóir nasctha tábhachtach le haghaidh macasamhlú víreasach. Úsáideann víris an gabhdóir AhR chun an córas imdhíonachta a sheachbhóthar agus meicníochtaí endogenous a bhlocáil, rud a chuireann cosc ar mhacasamhlú víreasach. In éineacht le MercachemSyncom, déanfaidh Hercules Pharmaceuticals a chomhdhúil luaidhe HP163 a bharrfheabhsú a thuilleadh do COVID-19 i dtreo an chlinic. (Irish)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Virus COVID-19 má za následek závažné společenské a hospodářské škody na celém světě. Mnoho lidí umírá na koronavirus a tlak na zdravotní péči je nesmírně vysoký. V boji proti pandemii mnoho zemí zavedlo (částečné) omezení volného pohybu osob. To vede k nižší míře šíření nákazy, ale má také významné negativní dopady na hospodářství. Proto je pro virus COVID-19 velmi zapotřebí vakcína nebo léčivý přípravek, pokud možno ústně. Přípravek Hercules Pharmaceuticals působí na inhibitory Aryl uhlovodíkového receptoru (AhR). AhR receptor byl identifikován jako důležitý spojovací faktor pro replikaci virů. Viry používají AhR receptor k obejití imunitního systému a blokování endogenních mechanismů, čímž se zabrání replikaci virů. Společně s MercachemSyncom bude Hercules Pharmaceuticals dále optimalizovat svou olovo HP163 pro COVID-19 směrem ke klinice. (Czech)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+O vírus da COVID-19 provoca graves danos societais e económicos em todo o mundo. Muitas pessoas morrem do vírus Corona e a pressão sobre os cuidados de saúde é imensamente alta. Para combater a pandemia, muitos países puseram em prática um confinamento (parcial). Tal resulta numa taxa de contágio mais baixa, mas também tem efeitos negativos significativos na economia. Por conseguinte, existe uma grande necessidade de uma vacina ou de um medicamento, de preferência por via oral, para o vírus da COVID-19. A Hercules Pharmaceuticals atua em inibidores para o Recetor de Hidrocarbonetos Arílicos (AhR). O recetor AhR foi identificado como um importante fator de ligação para as replicações virais. Os vírus utilizam o recetor AhR para contornar o sistema imunitário e bloquear os mecanismos endógenos, prevenindo as replicações virais. Juntamente com a MercachemSyncom, a Hercules Pharmaceuticals otimizará ainda mais o seu composto de chumbo HP163 para a COVID-19 para a clínica. (Portuguese)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+COVID-19 viirus põhjustab kogu maailmas suurt ühiskondlikku ja majanduslikku kahju. Paljud inimesed surevad koroonaviirusesse ja surve tervishoiule on tohutult suur. Pandeemia vastu võitlemiseks on paljud riigid kehtestanud (osalise) liikumispiirangu. Selle tulemuseks on väiksem edasikandumise määr, kuid sellel on ka märkimisväärne negatiivne mõju majandusele. Seetõttu on COVID-19 viiruse vastu vaja vaktsiini või ravimit, eelistatavalt suu kaudu. Hercules Pharmaceuticals toimib Aryl süsivesinike retseptori (AhR) inhibiitoritega. AhR-retseptorit peetakse viiruse replikatsiooni oluliseks ühendavaks teguriks. Viirused kasutavad AhR-retseptorit immuunsüsteemist mööda hiilimiseks ja endogeensete mehhanismide blokeerimiseks, vältides viiruse replikatsioone. Koos MercachemSyncomiga optimeerib Hercules Pharmaceuticals veelgi oma juhtühendit HP163 COVID-19 jaoks kliiniku suunas. (Estonian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+A Covid19-vírus világszerte jelentős társadalmi és gazdasági károkat okoz. Sokan halnak meg a Corona vírusban, és az egészségügyi ellátásra nehezedő nyomás mérhetetlenül magas. A világjárvány elleni küzdelem érdekében számos ország (részleges) kijárási tilalmat vezetett be. Ez alacsonyabb fertőzési arányt eredményez, de a gazdaságra is jelentős negatív hatást gyakorol. Ezért nagy szükség van a Covid19-vírus elleni oltóanyagra vagy gyógyszerre, lehetőleg szóban. A Hercules Pharmaceuticals az Aryl szénhidrogén-receptor (AhR) inhibitorain dolgozik. Az AhR receptort a vírusreplikációk fontos összekötő tényezőjeként azonosították. A vírusok az AhR receptort használják az immunrendszer megkerülésére és az endogén mechanizmusok blokkolására, megakadályozva a vírus replikációit. A MercachemSyncom-mal együtt a Hercules Pharmaceuticals tovább optimalizálja a HP163 ólomvegyületét a Covid19-re a klinikára. (Hungarian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Вирусът COVID-19 води до значителни обществени и икономически щети в световен мащаб. Много хора умират от коронавируса и натискът върху здравеопазването е изключително висок. За да се борят с пандемията, много държави въведоха (частично) ограничителни мерки. Това води до по-ниска степен на разпространение, но също така оказва значително отрицателно въздействие върху икономиката. Поради това съществува голяма нужда от ваксина или лекарство, за предпочитане устно, за вируса на COVID-19. Hercules Pharmaceuticals действа върху инхибитори на Aryl Hydrocarbon Receptor (AhR). AhR рецепторът е идентифициран като важен свързващ фактор за вирусните репликации. Вирусите използват AhR рецептора, за да заобиколят имунната система и блокират ендогенните механизми, предотвратявайки вирусните репликации. Заедно с MercachemSyncom, Hercules Pharmaceuticals ще оптимизира допълнително своето оловно съединение HP163 за COVID-19 към клиниката. (Bulgarian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+COVID-19 virusas daro didelę žalą visuomenei ir ekonomikai visame pasaulyje. Daugelis žmonių miršta nuo koronaviruso, o spaudimas sveikatos priežiūrai yra nepaprastai didelis. Siekdamos kovoti su pandemija, daugelis šalių nustatė (dalinį) izoliavimą. Tai lemia mažesnį užkrato užkratą, tačiau taip pat daro didelį neigiamą poveikį ekonomikai. Todėl COVID-19 virusui gydyti labai reikalinga vakcina arba vaistas, pageidautina žodžiu. Hercules Pharmaceuticals veikia Aryl Hydrocarbon Receptor (AhR) inhibitorius. Nustatyta, kad AhR receptorius yra svarbus viruso replikacijų jungiamasis veiksnys. Virusai naudoja AhR receptorius, kad aplenktų imuninę sistemą ir blokuotų endogeninius mechanizmus, taip užkertant kelią virusų replikacijoms. Kartu su MercachemSyncom Hercules Pharmaceuticals toliau optimizuos savo švino junginį HP163 COVID-19 link klinikos. (Lithuanian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Virus COVID-19 uzrokuje veliku društvenu i gospodarsku štetu diljem svijeta. Mnogi ljudi umiru od virusa koronavirusa, a pritisak na zdravstvenu skrb iznimno je visok. U cilju borbe protiv pandemije mnoge su zemlje uspostavile (djelomično) ograničenje kretanja. To dovodi do niže stope zaraze, ali ima i znatne negativne učinke na gospodarstvo. Stoga postoji velika potreba za cjepivom ili lijekom, po mogućnosti oralno, za virus COVID-19. Hercules Pharmaceuticals djeluje na inhibitore za Aryl Hydrocarbon Receptor (AhR). AhR receptor je identificiran kao važan povezujući faktor za virusne replikacije. Virusi koriste AhR receptor kako bi zaobišli imunološki sustav i blokirali endogene mehanizme, sprječavajući virusne replikacije. Zajedno s MercachemSyncomom Hercules Pharmaceuticals dodatno će optimizirati svoj olovni spoj HP163 za COVID-19 prema klinici. (Croatian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Covid-19-viruset leder till stora samhälleliga och ekonomiska skador i hela världen. Många människor dör av coronaviruset och trycket på hälso- och sjukvården är enormt högt. För att bekämpa pandemin har många länder infört en (delvis) nedstängning. Detta leder till en lägre spridningstakt men har också betydande negativa effekter på ekonomin. Det finns därför ett stort behov av ett vaccin eller ett läkemedel, helst oralt, för covid-19-viruset. Hercules Pharmaceuticals verkar på inhibitorer för Aryl Hydrocarbon Receptor (AhR). AhR-receptorn har identifierats som en viktig kopplingsfaktor för virusreplikationer. Virus använder AhR-receptorn för att kringgå immunsystemet och blockera endogena mekanismer, vilket förhindrar virusreplikationer. Tillsammans med MercachemSyncom kommer Hercules Pharmaceuticals att ytterligare optimera sin blyförening HP163 för covid-19 mot kliniken. (Swedish)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Virusul COVID-19 are ca rezultat daune societale și economice majore la nivel mondial. Mulți oameni mor din cauza virusului Corona, iar presiunea asupra asistenței medicale este extrem de ridicată. Pentru a combate pandemia, multe țări au instituit o izolare (parțială). Acest lucru duce la o rată de contagiune mai scăzută, dar are, de asemenea, efecte negative semnificative asupra economiei. Prin urmare, există o mare nevoie de un vaccin sau de un medicament, de preferință oral, pentru virusul COVID-19. Hercules Pharmaceuticals acționează asupra inhibitorilor pentru receptorul de hidrocarburi de aril (AhR). Receptorul AhR a fost identificat ca fiind un factor de legătură important pentru replicarea virală. Virusurile utilizează receptorul AhR pentru a ocoli sistemul imunitar și pentru a bloca mecanismele endogene, prevenind replicarea virală. Împreună cu MercachemSyncom, Hercules Pharmaceuticals își va optimiza în continuare compusul de plumb HP163 pentru COVID-19 către clinică. (Romanian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Virus COVID-19 povzroča veliko družbeno in gospodarsko škodo po vsem svetu. Veliko ljudi umre zaradi koronavirusa in pritisk na zdravstveno varstvo je izjemno velik. V boju proti pandemiji so številne države uvedle (delno) omejitev gibanja. Posledica tega je nižja stopnja širjenja negativnih vplivov, vendar ima tudi znatne negativne učinke na gospodarstvo. Zato obstaja velika potreba po cepivu ali zdravilu, po možnosti ustno, za virus COVID-19. Zdravilo Hercules Pharmaceuticals deluje na zaviralcih aril-ogljikovega receptorja (AhR). AhR receptor je bil opredeljen kot pomemben povezovalni dejavnik za virusne replikacije. Virusi uporabljajo receptor AhR za obvod imunskega sistema in blokiranje endogenih mehanizmov, s čimer preprečujejo razmnoževanje virusov. Podjetje Hercules Pharmaceuticals bo skupaj z MercachemSyncom še naprej optimiziralo svojo svinčeno spojino HP163 za COVID-19 v smeri klinike. (Slovenian)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / summary @@
+Wirus COVID-19 powoduje poważne szkody społeczne i gospodarcze na całym świecie. Wiele osób umiera z powodu wirusa koronawirusa, a presja na opiekę zdrowotną jest niezwykle wysoka. Aby zwalczać pandemię, wiele krajów wprowadziło (częściowe) środki izolacji. Skutkuje to niższym wskaźnikiem efektu domina, ale ma również znaczący negatywny wpływ na gospodarkę. W związku z tym istnieje duże zapotrzebowanie na szczepionkę lub lek, najlepiej doustnie, przeciwko wirusowi COVID-19. Hercules Pharmaceuticals działa na inhibitorach receptora węglowodorów Aryl (AhR). Receptor AhR został zidentyfikowany jako ważny czynnik łączący replikacje wirusowe. Wirusy wykorzystują receptor AhR do ominięcia układu odpornościowego i blokowania mechanizmów endogennych, zapobiegając replikacji wirusa. Wraz z MercachemSyncom Hercules Pharmaceuticals dodatkowo zoptymalizowa swój związek ołowiu HP163 pod kątem COVID-19 w kierunku kliniki. (Polish)
+Normal rank
+point in time: 21 August 2022Timestamp +2022-08-21T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2022-08-21T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / beneficiary name (string) @@
+Hercules Pharmaceuticals
@@ Property / beneficiary name (string): Hercules Pharmaceuticals / rank @@
+Normal rank
@@ Property / beneficiary name (string) @@
+Syncom
@@ Property / beneficiary name (string): Syncom / rank @@
+Normal rank
@@ Property / beneficiary @@
+Q3985407
@@ Property / beneficiary: Q3985407 / rank @@
+Normal rank
@@ Property / beneficiary @@
+Q3985039
@@ Property / beneficiary: Q3985039 / rank @@
+Normal rank
@@ Property / EU contribution @@
+,362.0 EuroAmount 399,362.0 Euro
Unit Euro
-Amount
+,362.0 Euro
-Unit
+Euro
@@ Property / EU contribution: 399,362.0 Euro / rank @@
+Normal rank
@@ Property / budget @@
+,362.0 EuroAmount 399,362.0 Euro
Unit Euro
-Amount
+,362.0 Euro
-Unit
+Euro
@@ Property / budget: 399,362.0 Euro / rank @@
+Normal rank
@@ Property / co-financing rate @@
+.0 percentAmount 100.0 percent
Unit percent
-Amount
+.0 percent
-Unit
+percent
@@ Property / co-financing rate: 100.0 percent / rank @@
+Normal rank

Latest revision as of 02:49, 11 October 2024

Project Q3988868 in Netherlands

Language	Label	Description	Also known as
English	Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients	Project Q3988868 in Netherlands

Statements

contained in NUTS

Agglomeratie Leiden en Bollenstreek

0 references

0 references

0 references

0 references

0 references

399,362.0 Euro

0 references

budget

399,362.0 Euro

0 references

co-financing rate

100.0 percent

0 references

start time

1 June 2020

0 references

end time

1 June 2021

0 references

beneficiary name (string)

Hercules Pharmaceuticals

0 references

Syncom

0 references

0 references

0 references

Research and innovation processes in SMEs (including voucher schemes, process, design, service and social innovation)

0 references

programme

North Netherlands - ERDF

0 references

fund

European Regional Development Fund

0 references

coordinate location

53°14'32.42"N, 6°31'47.86"E

0 references

52°10'7.79"N, 4°28'2.14"E

0 references

postal code

2333BD

0 references

9747AT

0 references

summary

Het COVID-19 virus resulteert wereldwijd in een grote maatschappelijke en economische schade. Tal van mensen overlijden aan het Corona virus en de druk op de gezondheidszorg is immens hoog. Om de pandemie te bestrijden hebben veel landen een (gedeeltelijke) lockdown ingesteld. Dit resulteert in een geringere besmettingsgraad maar heeft ook significante negatieve effecten op de economie. Er is dan ook een grote behoefte aan een vaccin of medicijn, bij voorkeur oraal, voor het COVID-19 virus. Hercules Pharmaceuticals werkt aan inhibitoren voor de Aryl Hydrocarbon Receptor (AhR). De AhR receptor is geïdentificeerd als een belangrijk aanknopingspunt voor virale replicaties. Virussen gebruiken de AhR receptor om het immuunsysteem te omzeilen en endogene mechanismes, die virale replicaties verhinderen, te blokkeren. Samen met het bedrijf MercachemSyncom gaat Hercules Pharmaceuticals haar lead compound HP163 voor COVID-19 verder optimaliseren richting de kliniek. (Dutch)

0 references

The COVID-19 virus results in a major societal and economic damage worldwide. Many people die of the Corona virus and the pressure on healthcare is immensely high. To combat the pandemic, many countries have put in place a (partial) lockdown. This results in a lower contagion rate but also has significant negative effects on the economy. There is therefore a great need for a vaccine or medicine, preferably orally, for the COVID-19 virus. Hercules Pharmaceuticals works on inhibitors for the Aryl Hydrocarbon Receptor (AhR). The AhR receptor has been identified as an important connecting factor for viral replications. Viruses use the AhR receptor to bypass the immune system and block endogenous mechanisms, preventing viral replications. Together with MercachemSyncom, Hercules Pharmaceuticals will further optimise its lead compound HP163 for COVID-19 towards the clinic. (English)

Development of AhR inhibitors for oral antiviral therapy for COVID-19 patients (Q3988868): Difference between revisions

Latest revision as of 02:49, 11 October 2024

Statements

Identifiers

Navigation menu

Search